08.08.2011 • NewsPeopleWarner ChilcottQ2 2011

Warner Chilcott Posts Lower Q2 Profit

Warner Chilcott reported second-quarter net income of $72 million or $0.28 per share versus $115 million or $0.46 per share last year. Cash net income, or CNI, for the quarter declined to $221 million from $269 million in the year-ago quarter. Adjusted CNI was $240 million, a decrease of $1 million or 1% from $241 million in the prior-year quarter.

Analysts polled by Thomson Reuters expected the company to earn $0.89 per share in the quarter. Analysts' estimates typically exclude special items.
Quarterly revenues decreased to $670.29 million from $815.61 million in the previous year. The Street estimated revenues of $675.49 million for the quarter.

Looking forward to 2011, the company reaffirmed its adjusted CNI per share forecast of $3.70 to $3.80.

Further, the company said it continues to expect its 2011 revenue to be in the range of $2.7 billion to $2.8 billion based on current revenue trends. The company added that it no longer expect revenue to be at the high end of our range as previously disclosed.

Analysts currently estimate earnings of $3.79 per share on revenues of $2.80 billion for the year.

In a separate release, Warner Chilcott said in connection with a realignment of its sales organization, Hans van Zoonen will head the company's North American sales organization effective immediately. The company added that in connection with the realignment, Carl Reichel, president, pharmaceuticals, will be leaving the company to pursue other interests.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.